Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Me... | NCT00443027

Studies
Effect Of Menstrual Cycle On Vaginal Blood Flow In Pre-Menopausal Healthy Women.

NCT00443027

Sponsor

Pfizer

Status

Completed

Last Update Posted

May 28, 2019Actual

Enrollment

12Estimated

Phase

Phase 1

Conditions

Sexual Dysfunction, Physiological

Interventions

Vaginal Heat Wash-Out Device

Countries

Australia

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

May 2019

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Mar 2007

Primary Completion Date

Oct 2008Actual

Completion Date

Oct 2008Actual

First Submitted Date

Mar 2, 2007

First Submission Date that Met QC Criteria

Mar 2, 2007

First Posted Date

Mar 5, 2007Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

May 23, 2019

Last Update Posted Date

May 28, 2019Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The Pfizer developed Heat Wash-Out (HWO) system is a software controlled electromechanical system designed to measure vaginal wall blood flow. A small vaginal probe is attached to a control unit. Output data is collected on a PC. By measuring the clearance of heat from the heated probe, a direct measure of absolute blood flow can be obtained. The study will assess changes in vaginal blood flow across the menstrual cycle following visual sexual stimulation.

Detailed Description

Medical Device Development

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

12Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Vaginal Heat Wash-Out Device	Experimental		Device: Vaginal Heat Wash-Out Device

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Vaginal Heat Wash-Out Device	Device	No drug administered. Device tested three times with each subject.	Vaginal Heat Wash-Out Device

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
To investigate differences in vaginal blood flow across the menstrual cycle following visual sexual stimulation.		28d
To assess the safety and toleration of the heat washout device.		28d

Secondary Outcomes

Measure	Description	Time Frame
To investigate changes in subjective acute sexual arousal following visual sexual stimulation across the menstrual cycle.		28d

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Pre-menopausal healthy women aged 18-45 with regular, natural menstrual cycles.
Subjects must be void of Female Sexual Disorder.

Exclusion Criteria:

Pregnant or lactating women
Postmenopausal subjects
Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric or neurologic disease.

Accepts Healthy Volunteers

Yes

Sex

Female

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

45 Years

Standard Ages

Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Pfizer CT.gov Call Center	Pfizer	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Pfizer Investigational Site		Dulwich	South Australia	5065	Australia
Pfizer Investigational Site

References Module

Citations

Not provided

ID	Term
D000091662	Genital Diseases
D000091642	Urogenital Diseases